Gene Silencing News and Research RSS Feed - Gene Silencing News and Research

Regen BioPharma develops novel means of delivering RGBP-248 gene silencing nucleic acid to liver tumors

Regen BioPharma develops novel means of delivering RGBP-248 gene silencing nucleic acid to liver tumors

Regen BioPharma, Inc. announced today development of a novel means of delivering its patented (US Patent 8,263,571) gene silencing nucleic acid, RGBP-248, to liver tumors utilizing a clinically approved formulation as delivery system. The product in development overcomes previous hurdles with gene silencing therapeutics in which the gene silencing drug had to be delivered throughout the whole body. [More]
Regen BioPharma implements gene silencing technology in killing cancer stem cells

Regen BioPharma implements gene silencing technology in killing cancer stem cells

Regen BioPharma Inc. reported today the successful implementation of its gene silencing technology, covered by patent # 8,263,571, in killing cancer stem cells. [More]
Benitec Biopharma announces closing of U.S. initial public offering of ADSs

Benitec Biopharma announces closing of U.S. initial public offering of ADSs

Benitec Biopharma Limited, a clinical-stage biotechnology company, is pleased to announce the closing of its U.S. initial public offering of 1,500,000 American Depositary Shares (ADSs), representing 30,000,000 fully paid ordinary shares of Benitec, together with warrants to purchase 500,000 ADSs, representing 10,000,000 fully paid ordinary shares. [More]
Benitec prices initial public offering of 1,500,000 American Depositary Shares

Benitec prices initial public offering of 1,500,000 American Depositary Shares

Benitec Biopharma Limited, a clinical-stage biotechnology company, is pleased to announce the pricing of its U.S. initial public offering of 1,500,000 American Depositary Shares (ADSs), representing 30,000,000 fully paid ordinary shares of Benitec and warrants to purchase 500,000 ADSs, representing 10,000,000 fully paid ordinary shares, at a price of US$9.21 per ADS and US$0.01 per warrant. [More]
Trends, R&D progress, and predicted revenues in RNAi therapies

Trends, R&D progress, and predicted revenues in RNAi therapies

When will RNAi therapies reach the market? Visiongain's brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there. [More]
Vital molecular mechanism in plants has similarities to certain signaling mechanisms in humans

Vital molecular mechanism in plants has similarities to certain signaling mechanisms in humans

Scientists at Van Andel Research Institute have revealed an important molecular mechanism in plants that has significant similarities to certain signaling mechanisms in humans, which are closely linked to early embryonic development and to diseases such as cancer. [More]
Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that data from its Phase I/II study of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published in Nature Medicine. [More]
Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

Benitec Biopharma is pleased to announce the launch of a new exploratory cellular therapy program including exosome-based delivery utilising the Company's proprietary ddRNAi technology. Entry into these areas have been facilitated by the commencement of a collaboration with UK-based stem cell therapeutics company, ReNeuron. [More]
New understanding of how Huntington's disease gene works

New understanding of how Huntington's disease gene works

Huntington's disease is caused by a mutation in the Huntington's disease gene, but it has long been a mystery why some people with the exact same mutation get the disease more severely and earlier than others. A closer look at the DNA around the Huntington's disease (HD) gene offers researchers a new understanding of how the gene is controlled and how this affects the disease. [More]
Scientists identify small RNA molecule that can suppress cancer-causing genes in GBM

Scientists identify small RNA molecule that can suppress cancer-causing genes in GBM

Northwestern Medicine scientists have identified a small RNA molecule called miR-182 that can suppress cancer-causing genes in mice with glioblastoma mulitforme (GBM), a deadly and incurable type of brain tumor. [More]
Rigontec raises €4.8 million in second closing of Series A financing round

Rigontec raises €4.8 million in second closing of Series A financing round

Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, today announces it has raised €4.8 million in a second closing of its Series A financing round from Forbion Capital Partners, a Dutch life-sciences venture capital firm, and Sunstone Capital, a Copenhagen based venture capital investor. [More]
Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," today announced that the fourth patient in the company's Phase I/IIa dose escalation clinical trial of its lead program TT-034 for treating hepatitis C was dosed at the Duke Clinical Research Unit. [More]
Combination therapies may overcome resistance to targeted cancer drugs

Combination therapies may overcome resistance to targeted cancer drugs

A protein called YAP, which drives the growth of organs during development and regulates their size in adulthood, plays a key role in the emergence of resistance to targeted cancer therapies, according to a new study led by UC San Francisco researchers. [More]
Parents can pass silenced genes to offspring through a specific mechanism

Parents can pass silenced genes to offspring through a specific mechanism

For more than a century, scientists have understood the basics of inheritance: if good genes help parents survive and reproduce, the parents pass those genes along to their offspring. And yet, recent research has shown that reality is much more complex: genes can be switched off, or silenced, in response to the environment or other factors, and sometimes these changes can be passed from one generation to the next. [More]
Phase IIb trial shows platinum-resistant ovarian patients treated with PM1183 live longer

Phase IIb trial shows platinum-resistant ovarian patients treated with PM1183 live longer

Zeltia announces today that its pharmaceutical division PharmaMar has data from a group of 33 randomized patients with platinum-resistant ovarian cancer demonstrating that PM1183 shows a significantly superior median overall survival compared to topotecan. [More]
TET1 enzyme may be important target for cancer diagnostics, treatment

TET1 enzyme may be important target for cancer diagnostics, treatment

Mutations in the KRAS gene have long been known to cause cancer, and about one third of solid tumors have KRAS mutations or mutations in the KRAS pathway. KRAS promotes cancer formation not only by driving cell growth and division, but also by turning off protective tumor suppressor genes, which normally limit uncontrolled cell growth and cause damaged cells to self-destruct. [More]
Janssen submits YONDELIS NDA for treatment of advanced soft tissue sarcoma

Janssen submits YONDELIS NDA for treatment of advanced soft tissue sarcoma

PharmaMar announces that Janssen Research & Development, LLC has submitted a New Drug Application (NDA) for YONDELIS (trabectedin) to the U.S. Food and Drug Administration for the treatment of patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy including an anthracycline. [More]
Researchers discover a new way to combat influenza virus infection

Researchers discover a new way to combat influenza virus infection

The influenza virus, like all viruses, is a hijacker. It quietly slips its way inside cells, steals the machinery inside to make more copies of itself, and then -- having multiplied -- bursts out of the cell to find others to infect. [More]
Dicer siRNA generation kit that mimics natural RNA interference introduced by AMSBIO

Dicer siRNA generation kit that mimics natural RNA interference introduced by AMSBIO

AMSBIO has introduced a Dicer siRNA Generation Kit that mimics the natural RNA interference process by using recombinant human dicer enzyme, a double-stranded RNA-specific endonuclease, to cleave in vitro transcribed dsRNA templates into a pool of 22 bp siRNAs. [More]
Promising new approach for combating colorectal cancer

Promising new approach for combating colorectal cancer

Scientists at the University of York are working on a promising new approach for tackling colorectal cancer, the second most common cause of cancer-related death. [More]
Advertisement
Advertisement